Alexion Pharmaceuticals Inc. [NASDAQ: ALXN] stock went on an upward path that rose over 0.29% on Wednesday, amounting to a one-week price increase of more than 2.25%. Over the last 12 months, ALXN stock dropped by -0.69%. The one-year Alexion Pharmaceuticals Inc. stock forecast points to a potential upside of 15.46. The average equity rating for ALXN stock is currently 2.10, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $25.78 billion, with 221.60 million shares outstanding and 218.86 million shares in the current float. Compared to the average trading volume of 2.62M shares, ALXN stock reached a trading volume of 1537007 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Alexion Pharmaceuticals Inc. [ALXN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALXN shares is $137.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALXN stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Alexion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 28, 2020. The new note on the price target was released on March 17, 2020, representing the official price target for Alexion Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $130 to $110, while BofA/Merrill kept a Neutral rating on ALXN stock.
The Average True Range (ATR) for Alexion Pharmaceuticals Inc. is set at 4.02, with the Price to Sales ratio for ALXN stock in the period of the last 12 months amounting to 4.87. The Price to Book ratio for the last quarter was 2.19, with the Price to Cash per share for the same quarter was set at 10.66. Price to Free Cash Flow for ALXN in the course of the last twelve months was 12.43 with Quick ratio for the last quarter at 3.80.
ALXN Stock Performance Analysis:
Alexion Pharmaceuticals Inc. [ALXN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.25. With this latest performance, ALXN shares gained by 14.79% in over the last four-week period, additionally plugging by 3.42% over the last 6 months – not to mention a drop of -0.69% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALXN stock in for the last two-week period is set at 62.20, with the RSI for the last a single of trading hit 61.23, and the three-weeks RSI is set at 60.69 for Alexion Pharmaceuticals Inc. [ALXN]. The present Moving Average for the last 50 days of trading for this stock 103.79, while it was recorded at 116.19 for the last single week of trading, and 103.22 for the last 200 days.
Insight into Alexion Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Alexion Pharmaceuticals Inc. [ALXN] shares currently have an operating margin of +42.45 and a Gross Margin at +85.79. Alexion Pharmaceuticals Inc.’s Net Margin is presently recorded at +48.53.
Return on Total Capital for ALXN is now 15.93, given the latest momentum, and Return on Invested Capital for the company is 18.56. Return on Equity for this stock inclined to 23.53, with Return on Assets sitting at 15.28. When it comes to the capital structure of this company, Alexion Pharmaceuticals Inc. [ALXN] has a Total Debt to Total Equity ratio set at 24.46. Additionally, ALXN Total Debt to Total Capital is recorded at 19.66, with Total Debt to Total Assets ending up at 15.72. Long-Term Debt to Equity for the company is recorded at 23.17, with the Long-Term Debt to Total Capital now at 18.62.
Reflecting on the efficiency of the workforce at the company, Alexion Pharmaceuticals Inc. [ALXN] managed to generate an average of $780,110 per employee. Receivables Turnover for the company is 4.58 with a Total Asset Turnover recorded at a value of 0.31.Alexion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.80 and a Current Ratio set at 4.30.
ALXN Stock EPS
With the latest financial reports released by the company, Alexion Pharmaceuticals Inc. posted 2.64/share EPS, while the average EPS was predicted by analysts to be reported at 2.34/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALXN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Alexion Pharmaceuticals Inc. go to 12.60%.
Alexion Pharmaceuticals Inc. [ALXN] Insider Position Details
There are presently around $23,250 million, or 93.20% of ALXN stock, in the hands of institutional investors. The top three institutional holders of ALXN stocks are: VANGUARD GROUP INC with ownership of 17,178,711, which is approximately 2.471% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 16,510,976 shares of the stock with an approximate value of $1.92 billion in ALXN stocks shares; and FMR LLC, currently with $1.38 billion in ALXN stock with ownership of nearly -19.12% of the company’s market capitalization.
Positions in Alexion Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 354 institutional holders increased their position in Alexion Pharmaceuticals Inc. [NASDAQ:ALXN] by around 22,023,707 shares. Additionally, 331 investors decreased positions by around 24,542,615 shares, while 68 investors held positions by with 153,880,632 shares. The mentioned changes placed institutional holdings at 200,446,954 shares, according to the latest SEC report filing. ALXN stock had 79 new institutional investments in for a total of 4,995,106 shares, while 93 institutional investors sold positions of 1,658,426 shares during the same period.